Comparative Pharmacology
Head-to-head clinical analysis: MIRALAX versus PLEGISOL IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRALAX versus PLEGISOL IN PLASTIC CONTAINER.
MIRALAX vs PLEGISOL IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polyethylene glycol 3350 (PEG 3350) is an osmotic laxative that works by retaining water in the stool through hydrogen bonding, increasing fecal water content and promoting bowel movements.
PLEGISOL is an extracellular-type crystalloid cardioplegic solution used for myocardial protection during cardiac surgery. Its mechanism involves inducing rapid cardiac arrest by high potassium concentration (depolarizing arrest), reducing myocardial oxygen demand, and providing buffering capacity via tromethamine to maintain pH. The solution also contains magnesium to stabilize membranes and mannitol as an osmotic agent to reduce edema.
17 g (1 heaping tablespoon) dissolved in 4–8 oz of water, juice, soda, coffee, or tea, administered orally once daily. Maximum duration of use: 7 days.
Administered as an intraperitoneal infusion for organ preservation. Typical adult dose: 2.5-3.0 liters for kidney, 2.5-3.0 liters for liver, 3.0-4.0 liters for pancreas, single dose prior to procurement.
None Documented
None Documented
Not applicable; polyethylene glycol 3350 is minimally absorbed and systemic half-life is not clinically relevant.
Not applicable; Plegisol is not a systemically active drug. Its cardioplegic effect is immediate upon perfusion into coronary arteries and dissipates upon reperfusion. The solution's components have endogenous half-lives (e.g., potassium: 1-1.5 h in plasma), but this is not clinically relevant for the product.
Primarily excreted unchanged in feces (>90% of oral dose); negligible renal elimination (<0.1% recovered in urine).
Plegisol is an extracellular cardioplegic solution; its components (electrolytes and calcium) are not metabolized. Elimination of infused volume occurs primarily via renal excretion (approx. 95%) as unchanged water and electrolytes; minor biliary/fecal elimination (<5%) accounts for negligible electrolyte loss.
Category C
Category C
Osmotic Laxative
Osmotic Laxative